Skip to Content
Merck
CN

75517

Orphenadrine hydrochloride

≥98.0% (AT)

Synonym(s):

β-Dimethylaminoethyl 2-methylbenzhydryl ether hydrochloride, N,N-Dimethyl-2-(2-methylbenzhydryloxy)ethylamine hydrochloride, o-Methyldiphenhydramine hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C18H23NO · HCl
CAS Number:
341-69-5
Molecular Weight:
305.84
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
57652570
EC Number:
206-435-4
Beilstein/REAXYS Number:
3745818
MDL number:
MFCD00012480
Assay:
≥98.0% (AT)
Form:
powder

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

UQZKYYIKWZOKKD-UHFFFAOYSA-N

InChI

1S/C18H23NO.ClH/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16;/h4-12,18H,13-14H2,1-3H3;1H

SMILES string

Cl.CN(C)CCOC(c1ccccc1)c2ccccc2C

description

Drug Control: Új pszichoaktív anyag / New psychoactive substance (Hungary), 78/2022. (XII. 28.) BM rendelet.

assay

≥98.0% (AT)

form

powder

drug control

Új pszichoaktív anyag / New psychoactive substance (Hungary), 78/2022. (XII. 28.) BM rendelet

mp

160-164 °C

functional group

amine, ether, phenyl

Quality Level

100

Gene Information

human ... GRIN1(2902), GRIN2A(2903), GRIN2B(2904), GRIN2C(2905), GRIN2D(2906), GRIN3A(116443), GRIN3B(116444), HRH1(3269), SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335), SLC6A2(6530)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Muscarinic receptor antagonist; H1 histamine receptor antagonist; muscle relaxant. Orphenadrine has also been reported to inhibit the noradrenergic transporter and to block the NMDA receptor ion channel.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCK2674
BCBS5264V
BCBM3941V
BCBH4323V
BCBB3303V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mei-juan Xu et al.
Yao xue xue bao = Acta pharmaceutica Sinica, 42(7), 730-734 (2007-09-22)
To study the enzyme kinetics of schizandrin metabolism in different gender in rat liver microsomes, liver microsomes were prepared from male or female rats. Schizandrin was incubated with rat liver microsomes. Schizandrin and its metabolites were isolated and identified by
Daniel Sälinger et al.
Chemistry (Weinheim an der Bergstrasse, Germany), 15(27), 6688-6703 (2009-06-06)
Desymmetrizations of the prochiral bis(bromoaryl)alcohols 1 and 4 were effected by treatment with iPr2Mg and enantiomerically pure lithium alkoxides. The resulting arylmagnesium compounds were quenched with various electrophiles. The absolute and (if relevant) relative configurations of the resulting products were
Konrad Rejdak et al.
Brain research bulletin, 84(6), 389-393 (2011-01-29)
The current study was aimed to assess the convulsant potency of orphenadrine (ORPH) in rats together with a screen of different conventional antiepileptic drugs (AEDs) on their efficacy to suppress it. ORPH was administered intraperitoneally (i.p.) in doses of 50-80
Pål Gjerden et al.
British journal of clinical pharmacology, 67(2), 228-233 (2008-12-20)
Anticholinergic antiparkinson drugs are used to ameliorate extrapyramidal symptoms caused by either Parkinson's disease or antipsychotic drugs, but their use in the treatment of Parkinson's disease is assumed to be in decline. Patients with psychotic conditions have a high prevalence
Effect of warnings in a medical journal on the use of orphenadrine.
Pål Gjerden et al.
Journal of evaluation in clinical practice, 14(4), 615-617 (2008-05-09)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service